RKRolf Karlsten

Rolf Karlsten

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rolf Karlsten has a total of 169 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Opioid Use and Prescription Opioid Use Disorder: Biopsychosocial Characterisation of a Clinical Chronic Pain Cohort

    by Sofia Wagner, Hanna Ljungvall, Hedvig Zetterberg, Rolf Karlsten, Lisa Ekselius, Pernilla Åsenlöf

    Background: This study aimed to examine: (a) characteristics associated with long‐term opioid use and (b) characteristics associated with problematic opioid use, here defined as prescription opioid use disorder (P‐OUD), in patients referred to specialised pain care.Methods: This cross‐sectional study utilised baseline data from a clinical chronic pain cohort. Eligible participants included adults > 18 years old, not undergoing cancer treatment, had pain > 3 months, and had been referred to a specialised pain care centre in Sweden. Bivariate logistic regression and multivariable logistic regression with forward selection were used to examine the associations between biopsychosocial variables and either long‐term opioid use or P‐OUD.Results: Of the 339 patients included, 194 (57%) were using opioids, 159 (47%) had long‐term opioid use (> 90 days), and 34 (21% of those with long‐term opioid use) had P‐OUD. Longer pain duration, unemployment, more pain catastrophising, lower health‐related quality of life, and worse balance increased the likelihood of long‐term opioid use. Long‐term use of high doses was associated with a greater prevalence of psychiatric and cognitive‐behavioural problems compared to long‐term use at low to moderate doses. Long‐term opioid use, younger age, trauma exposure, more pain catastrophising, and fear of movement increased the likelihood of P‐OUD.Conclusions: Our results demonstrate the importance of identifying and treating salient factors that may sustain both the pain condition and long‐term opioid use. Many of the biopsychosocial variables associated with long‐term opioid use and P‐OUD can be addressed within interdisciplinary pain management and rehabilitation programmes.Significance: This study is part of the U‐PAIN cohort study on a clinical sample from a highly specialised pain centre in Sweden. It is based on a deep and thorough characterisation of patients referred to the clinic to evaluate risks and benefits of opioid therapy in chronic pain. It adds valuable information on the complexity of opioid therapy in chronic pain; the results highlight the need for interdisciplinary multimodal evaluation and treatment.


  • Sensor-Based Measurement of Nociceptive Pain: An Exploratory Study with Healthy Subjects

    by Mevludin Memedi, Adriana Miclescu, Lenka Katila, Marianne Claesson, Marie Essermark, Per Holm, Gunnar O. Klein, Jack Spira, Rolf Karlsten


  • Per-Protocol and Pre-Defined population analysis of the LINC study

    by Sten Rubertsson, Erik Lindgren, David Smekal, Ollie Östlund, Johan Silfverstolpe, Robert A. Lichtveld, Rene Boomars, Wendy Bruins, Björn Ahlstedt, Gunnar Skoog, et al.


    • 25 March 2015
      • Vol. 112

    [Not Available].

    by Torsten Gordh, Rolf Karlsten

  • Top Cited Papers

    Mechanical Chest Compressions and Simultaneous Defibrillation vs Conventional Cardiopulmonary Resuscitation in Out-of-Hospital Cardiac Arrest

    by Sten Rubertsson, Erik Lindgren, David Smekal, Ollie Östlund, Johan Silfverstolpe, Robert A. Lichtveld, Rene Boomars, Björn Ahlstedt, Gunnar Skoog, Robert Kastberg, et al.

    Research from JAMA — Mechanical Chest Compressions and Simultaneous Defibrillation vs Conventional Cardiopulmonary Resuscitation in Out-of-Hospital Cardiac Arrest — The LINC Randomized Trial


  • TRPV1 antagonistic analgesic effect: A randomized study of AZD1386 in pain after third molar extraction

    by Hans Quiding, Bror Jonzon, Ola Svensson, Lynn Webster, Annika Reimfelt, Aleksandra Karin, Rolf Karlsten, Märta Segerdahl

    The effects of a TRPV1 antagonist (AZD1386) were investigated in patients with acute pain. After removal of a mandibular third molar and at request of analgesia 103 patients randomly received 95 mg AZD1386 (n = 40), placebo (n = 40) or 500 mg naproxen (n = 23) in a double-blind manner. Plasma samples were drawn, and pain intensity and body temperature were measured during 8 h after drug administration. The pain intensity difference from drug intake was calculated as a percentage (PID%) and as a weighted sum over the 8 h (SPID%0-8 h). The time to first perceptible and first meaningful pain relief was recorded. SPID%(0-8) h showed no significant difference between AZD1386 and placebo (P = .132) but between naproxen and placebo (P = .038). AZD1386 had a rapid short-lasting analgesia and compared to placebo, PID% was significantly higher (P ≤ .026) at 0.25, 0.50, 0.75 and 1.00 h after drug administration. Correspondingly, for naproxen significantly higher PID% (P ≤ .021) was seen at 2.5, 3, 4, 5, 6, 7 and 8 h. The frequency of patients obtaining perceptible and meaningful pain relief was about 85% and 48% after AZD1386 and about 53% and 25% after placebo. The occurrence of perceptible and meaningful pain relief was significantly faster (P = .002 and P = .031) for AZD1386 compared to placebo. Adverse events were similar to placebo with the exception of 2 patients reporting chills. The highest individual body temperature after AZD1386 was 38.1°C, recorded in 2 patients. In summary, AZD1386 was well tolerated with a rapid analgesia that was short lasting despite sustained plasma concentration.


  • Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin‐induced pain and hyperalgesia

    by Jarkko Kalliomäki, Peter Annas, Karin Huizar, Cyril Clarke, Annika Zettergren, Rolf Karlsten, Märta Segerdahl

    Summary: The aim of the present study was to investigate the effects of AZD1940, a novel peripherally acting cannabinoid CB1/CB2 receptor agonist, on capsaicin‐induced pain and hyperalgesia, as well as on biomarkers of cannabinoid central nervous system (CNS) effects. The present study was a randomized, double‐blind, placebo‐controlled, four‐sequence, two‐period, cross‐over study in 44 male healthy volunteers aged 20–45 years. The effects of two single oral doses of AZD1940 (400 and 800 μg) were compared with placebo. Pain intensity after intradermal capsaicin injections in the forearm was assessed on a continuous visual analogue scale (VAS; 0–100 mm). Primary and secondary hyperalgesia induced by application of capsaicin cream on the calf were assessed by measuring heat pain thresholds and the area of mechanical allodynia, respectively. The CNS effects were assessed at baseline and up to 24 h after dosing using a visual analogue mood scales (VAMS) for feeling ‘stimulated’, ‘high’, ‘anxious’, ‘sedated’ or ‘down’. AZD1940 did not significantly attenuate ongoing pain or primary or secondary hyperalgesia compared with placebo. Mild CNS effects for AZD1940were observed on the VAMS for ‘high’ and ‘sedated’. Dose‐dependent mild‐to‐moderate CNS‐related and gastrointestinal adverse events were reported following treatment with AZD1940. No evidence of analgesic efficacy was found for a peripherally acting CB1/CB2 receptor agonist in the human capsaicin pain model. The emergence of mild dose‐dependent CNS effects suggests that the dose range predicted from preclinical data had been attained.


  • Open Access

    The Study Protocol for the LINC (LUCAS in Cardiac Arrest) Study: a study comparing conventional adult out-of-hospital cardiopulmonary resuscitation with a concept with mechanical chest compressions and simultaneous defibrillation

    by Sten Rubertsson, Johan Silfverstolpe, Liselott Rehn, Thomas Nyman, Rob Lichtveld, Rene Boomars, Wendy Bruins, Björn Ahlstedt, Helena Puggioli, Erik Lindgren, et al.

    The LUCAS™ device delivers mechanical chest compressions that have been shown in experimental studies to improve perfusion pressures to the brain and heart as well as augmenting cerebral blood flow and end tidal CO2, compared with results from standard manual cardiopulmonary resuscitation (CPR). Two randomised pilot studies in out-of-hospital cardiac arrest patients have not shown improved outcome when compared with manual CPR. There remains evidence from small case series that the device can be potentially beneficial compared with manual chest compressions in specific situations. This multicentre study is designed to evaluate the efficacy and safety of mechanical chest compressions with the LUCAS™ device whilst allowing defibrillation during on-going CPR, and comparing the results with those of conventional resuscitation.


  • Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal

    by Jarkko Kalliomäki, Märta Segerdahl, Lynn Webster, Annika Reimfelt, Karin Huizar, Peter Annas, Rolf Karlsten, Hans Quiding

    Aim: To evaluate the analgesic efficacy of AZD1940, a novel peripherally acting cannabinoid CB 1 /CB 2 receptor agonist, in patients undergoing third molar surgical removal. Methods: This was a randomized, double-blind, placebo-controlled study in patients scheduled for surgical removal of an impacted lower third molar. Patients received a single oral dose of 800 μg AZD1940, 500 mg naproxen or placebo 1.5 h before surgery. The dose of 800 μg AZD1940 was selected based on earlier data from a single dose study in man, in which it was identified as the highest well tolerated dose. Ongoing post-operative pain (primary variable) and pain on jaw movement were assessed on a visual analog scale (VAS, 0-100 mm) from 0 to 8h postoperatively, deriving the area under the curve of ongoing pain (VAS AUC 0–8h ), and of pain on jaw movement (VAS JM AUC 0–8h ). The time to requesting rescue medication (acetaminophen) was recorded. Subjective cannabinoid effects were assessed by the visual analog mood scale (VAMS). Results: In total, 151 patients were randomized to AZD1940 ( n = 61), placebo ( n = 59) or naproxen ( n = 31). There was no statistically significant difference in pain VAS AUC 0–8h or in VAS JM AUC 0–8h between AZD1940 and placebo. Naproxen significantly reduced both pain VAS AUC 0–8h and VAS JM AUC 0–8h as compared with placebo ( p < 0.0001 for both). Significantly fewer patients on naproxen requested rescue medication and the duration of time to rescue was greater, as compared with placebo, whereas there were no significant differences between AZD1940 and placebo in these outcome variables. Statistically significant increases in VAMS items “sedated” and “high” were observed after AZD1940 compared with placebo. The increases in VAMS were numerically small compared with previous findings with a centrally acting cannabinoid. The most commonly observed adverse events (AE) on treatment with AZD1940 were postural dizziness (80% of subjects), nausea (26%), hypotension (21%) and headache (13%), most AE being mild to moderate. Conclusion: The CB 1 /CB 2 receptor agonist AZD1940 did not reduce post-operative pain after lower third molar surgical removal at doses exerting subjective cannabinoid effects. Implications: Activation of peripheral CB 1 /CB 2 receptors per se is probably of less clinical relevance for the treatment of acute nociceptive pain in man.